JUNTEN BIO Co., Ltd. was established as Juntendo University’s venture company on the basis of Juntendo University’s research seeds.
Our aim is to develop a novel type of cell therapy in Japan and thus to contribute to the global healthcare industry.
With Juntendo University’s research seeds as the basis, we have studied the mechanism of immune rejection within the body, resulting in successful preparation of inducible inhibitory
T-cells.
Our aim is to achieve the induction of immune tolerance (and the discontinuation of immunosuppressant administration) with a new treatment using these inducible inhibitory
T-cells.
At the present time, clinical studies are being performed on cell therapy for specific inhibition of immunity associated with living-donor liver transplants, using inducible inhibitory T-cells.
・Development of cellular medicines for cell therapy for
living-donor liver transplants, late living-donor liver transplants
(i.e. a considerable time after transplantation),
and brain-dead liver transplants.
・Development of cell therapy and antibody drugs for living-donor kidney transplants.
November 7, 2023
Concluded a license agreement with AlliedCel Corporation.
JUNTEN BIO Co., Ltd has Concluded a license agreement with AlliedCel Corporation, a Joint Venture Between Sysmex and JCR Pharmaceuticals.
Sysmex Corporation News Release
https://www.sysmex.co.jp/en/news/2023/231107.html
JCR Pharmaceuticals News Release
November 1, 2023
Notice Regarding the Issue of Unsecured Straight Bonds
JUNTEN BIO Co., Ltd. announced on October 31, 2023 that it has issued corporate bond and share acquisition right to Mizuho venture debt fund. This topic is the first case with Mizuho venture debt fund.
July 6, 2022
The article introducing our company was published in the Nikkei (morning newspaper, July 6, 2022).
https://www.nikkei.com/
January 31, 2022
Juntendo Immune Tolerance Project website had been updated.
November 26, 2021
Juntendo Immune Tolerance Project website had been updated.
